Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
7 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Impact of Trabectedin Interruption and Subsequent Rechallenge on Progression in Patients With Advanced Soft Tissue Sarcoma: Long-term Follow-up of the T-DIS trial.
Am J Clin Oncol. 2018 Nov;41(11):1094-1100. doi: 10.1097/COC.0000000000000430.
Am J Clin Oncol. 2018.
PMID: 29509592
Exceptional Long-lasting Clinical Benefit of Trabectedin in a Patient With Metastatic Undifferentiated Pleomorphic Sarcoma: Postscriptum From the T-Dis Trial.
Penel N, Decoupigny E, Tresch-Bruneel E, Le Cesne A, Taieb S, Isambert N.
Penel N, et al. Among authors: decoupigny e.
Am J Clin Oncol. 2019 Sep;42(9):737. doi: 10.1097/COC.0000000000000576.
Am J Clin Oncol. 2019.
PMID: 31449140
No abstract available.
Item in Clipboard
Circulating vascular endothelial growth factor (VEGF) as predictive factor of progression-free survival in patients with advanced chordoma receiving sorafenib: an analysis from a phase II trial of the french sarcoma group (GSF/GETO).
Lebellec L, Bertucci F, Tresch-Bruneel E, Bompas E, Toiron Y, Camoin L, Mir O, Laurence V, Clisant S, Decoupigny E, Blay JY, Goncalves A, Penel N.
Lebellec L, et al. Among authors: decoupigny e.
Oncotarget. 2016 Nov 8;7(45):73984-73994. doi: 10.18632/oncotarget.12172.
Oncotarget. 2016.
PMID: 27659533
Free PMC article.
Item in Clipboard
REGOSARC: Regorafenib versus placebo in doxorubicin-refractory soft-tissue sarcoma-A quality-adjusted time without symptoms of progression or toxicity analysis.
Berry V, Basson L, Bogart E, Mir O, Blay JY, Italiano A, Bertucci F, Chevreau C, Clisant-Delaine S, Liegl-Antzager B, Tresch-Bruneel E, Wallet J, Taieb S, Decoupigny E, Le Cesne A, Brodowicz T, Penel N.
Berry V, et al. Among authors: decoupigny e.
Cancer. 2017 Jun 15;123(12):2294-2302. doi: 10.1002/cncr.30661. Epub 2017 Mar 10.
Cancer. 2017.
PMID: 28295221
Free PMC article.
Clinical Trial.
Item in Clipboard
A double-blind placebo-controlled randomized phase II trial assessing the activity and safety of regorafenib in non-adipocytic sarcoma patients previously treated with both chemotherapy and pazopanib.
Penel N, Mir O, Wallet J, Ray-Coquard I, Le Cesne A, Italiano A, Salas S, Delcambre C, Bompas E, Bertucci F, Saada-Bouzid E, Chaigneau L, Chevreau C, Brodowicz T, Decoupigny E, Vanseymortier M, Laroche L, Taieb S, Le Deley MC, Blay JY.
Penel N, et al. Among authors: decoupigny e.
Eur J Cancer. 2020 Feb;126:45-55. doi: 10.1016/j.ejca.2019.12.001. Epub 2020 Jan 6.
Eur J Cancer. 2020.
PMID: 31918233
Clinical Trial.
Item in Clipboard
Assessing Prognostic and Predictive Biomarkers of Regorafenib Response in Patients with Advanced Soft Tissue Sarcoma: REGOSARC Study.
Brodowicz T, Liegl-Atzwanger B, Penel N, Mir O, Blay JY, Kashofer K, Le Cesne A, Decoupigny E, Wallet J, Hamacher R, Deley ML.
Brodowicz T, et al. Among authors: decoupigny e.
Cancers (Basel). 2020 Dec 12;12(12):3746. doi: 10.3390/cancers12123746.
Cancers (Basel). 2020.
PMID: 33322802
Free PMC article.
Item in Clipboard
Once weekly paclitaxel associated with a fixed dose of oral metronomic cyclophosphamide: a dose-finding phase 1 trial.
Pannier D, Adenis A, Bogart E, Dansin E, Clisant-Delaine S, Decoupigny E, Lesoin A, Amela E, Ducornet S, Meurant JP, Le Deley MC, Penel N.
Pannier D, et al. Among authors: decoupigny e.
BMC Cancer. 2018 Jul 31;18(1):775. doi: 10.1186/s12885-018-4678-x.
BMC Cancer. 2018.
PMID: 30064401
Free PMC article.
Clinical Trial.
Item in Clipboard
Cite
Cite